Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02153476 · ClinicalTrials.gov registry record · Phase 2
A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
A Phase 2 study of Symptomatic Focal Vitreomacular Adhesion, sponsored by Allegro Ophthalmics.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT02153476 is a Phase 2 study of Symptomatic Focal Vitreomacular Adhesion that has completed, run by Allegro Ophthalmics. The registered enrollment target is 45 participants. The trial reports 5 study locations across 3 states.
The verdict
NCT02153476, a Phase 2 study of Symptomatic Focal Vitreomacular Adhesion, has completed, sponsored by Allegro Ophthalmics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
Evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human subjects with symptomatic focal vitreomacular adhesion
Conditions Studied
Interventions
- DRUG 2.0mg of ALG-1001
- DRUG Balanced Salt Solution
Study Locations (5)
California
- Retina-Vitreous Associates Medical Group - Beverly Hills
- California Retina Consultants - Santa Barbara
Texas
- Austin Retina Associates - Austin
- Retina Consultants Houston - Houston
Florida
- Center for Retinal and Macular Disease - Winter Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02153476
The ClinicalTrials.gov registry entry for NCT02153476 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allegro Ophthalmics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Symptomatic Focal Vitreomacular Adhesion appearing as the primary indexed condition, and to 2 interventions - of which 2.0mg of ALG-1001 is the first listed.
NCT02153476 reports 5 study locations spanning 3 distinct geographic areas - top geographies include California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT02153476 about?
NCT02153476 is a clinical study titled "A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion". Evaluate the safety and efficacy of ophthalmic intravitreal injection of ALG-1001 in human subjects with symptomatic focal vitreomacular adhesion
What is the current status of trial NCT02153476?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2014-02. Estimated completion is 2015-06.
What conditions does trial NCT02153476 study?
This clinical trial studies the following conditions: Symptomatic Focal Vitreomacular Adhesion.
What interventions are being tested in trial NCT02153476?
The interventions under investigation include: 2.0mg of ALG-1001 (DRUG), Balanced Salt Solution (DRUG).
Who is sponsoring clinical trial NCT02153476?
This trial is sponsored by Allegro Ophthalmics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02153476 being conducted?
This trial has 5 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.